Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard-2024-226437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review.
Rheumatol Int
January 2025
Division of Hematology-Oncology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematological malignancies. Recently, CAR-T has been used in refractory auto-immune diseases with initial encouraging results. In this systematic review, we examined the safety and efficacy of CAR-T in patients with refractory auto-immune diseases.
View Article and Find Full Text PDFCD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
Ann Rheum Dis
November 2024
Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Tel Aviv, Israel.
Are we there yet? CAR-T therapy in multiple myeloma.
Br J Haematol
December 2024
School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
The last few years have seen a revolution in cellular immunotherapies for multiple myeloma (MM) with novel antigen targets. The principle new target is B-cell maturation antigen (BCMA). Autologous chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA was first approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2021, although approval by the National Institute for Health and Care Excellent (NICE) is awaited.
View Article and Find Full Text PDFSequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
Br J Haematol
December 2024
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, Muenster, Germany.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma, accounting for ~40% of all cases in adults. Whilst approximately two-thirds of DLBCL patients can be cured by first-line therapy, one-third of patients are primary refractory or relapse after an initial response (r/r DLBCL). Recent advances in the treatment of DLBCL have been achieved by a plethora of novel drugs, such as monoclonal antibodies, antibody-drug conjugates (ADC), bi-specific T-cell engagers (BITEs), and CD-19 directed chimeric antigen receptor (CAR)-T-cell therapies.
View Article and Find Full Text PDFOutcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review.
Transpl Immunol
December 2024
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States. Electronic address:
Background: Chimeric antigen receptor T cell (CAR-T) therapy is an emerging form of immunotherapy that has recently gained recognition for treating hematological malignancies. This successful utilization of CAR-T therapy has attracted interest in its application in refractory rheumatological diseases. Here, we will review the use of CAR-T therapy in rheumatological diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!